Wolverine Trading, LLC Alnylam Pharmaceuticals, Inc. Put Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Put Options

27 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $2.76 Million - $3.39 Million	-11,800 Reduced 30.97%	26,300 $7.23 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $2.04 Million - $3.51 Million	14,200 Added 59.41%	38,100 $9.26 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $1.29 Million - $1.74 Million	8,800 Added 58.28%	23,900 $3.57 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $620,781 - $805,937	4,100 Added 37.27%	15,100 $2.89 Million
Q3 2023 Nov 15, 2023	BUY	$170.77 - $211.65 $614,772 - $761,940	3,600 Added 48.65%	11,000 $1.95 Million
Q2 2023 Aug 23, 2023	SELL	$185.01 - $212.05 $536,529 - $614,945	-2,900 Reduced 28.16%	7,400 $1.41 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $876,768 - $1.13 Million	4,800 Added 87.27%	10,300 $2.01 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $129,871 - $168,917	-700 Reduced 11.29%	5,500 $1.31 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $761,970 - $1.28 Million	-5,500 Reduced 47.01%	6,200 $1.3 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $397,386 - $558,657	3,300 Added 39.29%	11,700 $1.7 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $559,592 - $765,204	-4,400 Reduced 34.38%	8,400 $1.39 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $1.04 Million - $1.36 Million	6,500 Added 103.17%	12,800 $2.19 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $3.43 Million - $4.2 Million	-20,200 Reduced 76.23%	6,300 $1.12 Million
Q2 2021 Aug 06, 2021	BUY	$128.63 - $176.89 $2.29 Million - $3.15 Million	17,800 Added 204.6%	26,500 $4.4 Million
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $431,222 - $597,346	-3,400 Reduced 28.1%	8,700 $1.18 Million
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $725,523 - $867,300	-5,900 Reduced 32.78%	12,100 $1.59 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $290,856 - $397,176	-2,400 Reduced 11.76%	18,000 $2.61 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $239,683 - $359,812	-2,300 Reduced 10.13%	20,400 $3.02 Million
Q1 2020 May 11, 2020	SELL	$93.12 - $133.99 $949,824 - $1.37 Million	-10,200 Reduced 31.0%	22,700 $2.47 Million
Q4 2019 Feb 12, 2020	BUY	$74.51 - $124.23 $149,020 - $248,460	2,000 Added 6.47%	32,900 $3.77 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $134,710 - $166,858	-1,900 Reduced 5.79%	30,900 $2.51 Million
Q2 2019 Aug 20, 2019	SELL	$65.86 - $92.79 $230,510 - $324,765	-3,500 Reduced 9.64%	32,800 $2.38 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $938,604 - $1.21 Million	-12,900 Reduced 26.22%	36,300 $3.39 Million
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $1.32 Million - $1.85 Million	-21,000 Reduced 29.91%	49,200 $3.46 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $2.2 Million - $3.08 Million	25,100 Added 55.65%	70,200 $6.14 Million
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $1.29 Million - $1.65 Million	-11,100 Reduced 19.75%	45,100 $5.37 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $6.43 Million - $7.87 Million	56,200	56,200 $7.14 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.06 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.32 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.27 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.2 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account